Dengue vaccine is a vaccine used to prevent dengue fever in humans. Development of dengue vaccines began in the 1920s but was hindered by the need to create immunity against all four dengue serotypes. As of 2023, there are two commercially available vaccines, sold under the brand names Dengvaxia and Qdenga. Dengvaxia is only recommended in those who have previously had dengue fever or populations in which most people have been previously infected due to a phenomenon known as antibody-dependent enhancement. The value of Dengvaxia is limited by the fact that it may increase the risk of severe dengue in those who have not previously been infected. In 2017, more than 733,000 children and more than 50,000 adult volunteers were vaccinated with Dengvaxia regardless of serostatus, which led to a controversy. Qdenga is designated for people not previously infected. There are other vaccine candidates in development including live attenuated, inactivated, DNA and subunit vaccines.
1*Dr. Pruthviraj K. Chaudhary, 1Dr. Dhiren L. Chaudhari, 1Shloka V. Chaudhari, 2Dr Devanshi Vijaykumar Chaudhary, 3Dr. Dhrubo Jyoti Sen (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: